Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Arcellx, Inc.
Arcellx, Inc.
Ryvu Therapeutics SA
Centre Hospitalier Universitaire de Nīmes
Guangzhou Lupeng Pharmaceutical Company LTD.
Ascentage Pharma Group Inc.
Foundation For Rare Disease Research
NexImmune Inc.
Assistance Publique - Hôpitaux de Paris
University of Tennessee
The First Affiliated Hospital of Soochow University
University of Birmingham
Alliance for Clinical Trials in Oncology
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Sohag University
Sohag University
Biocity Biopharmaceutics Co., Ltd.
Assiut University
Perseus Proteomics Inc.
University Hospital, Toulouse
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
The First Affiliated Hospital of Soochow University
AB Science
The First Affiliated Hospital of Soochow University
Mabwell (Shanghai) Bioscience Co., Ltd.
Centre Hospitalier Universitaire, Amiens
University of Kansas Medical Center
Korea Otsuka Pharmaceutical Co., Ltd.
Beijing Friendship Hospital
The University of Hong Kong
Multinational Center for Quality of Life Research, Russia
Shenzhen Second People's Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Assiut University
Taiga Biotechnologies, Inc.
Weprom
Chinese PLA General Hospital
Hospices Civils de Lyon
Changchun GeneScience Pharmaceutical Co., Ltd.
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
The First Affiliated Hospital of Soochow University
Guizhou Bailing Group Pharmaceutical Co Ltd
Nanfang Hospital, Southern Medical University
Grupo Cooperativo de Hemopatías Malignas
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Maxinovel Pty., Ltd.
Royal Free Hospital NHS Foundation Trust
Sun Yat-sen University
Nanfang Hospital, Southern Medical University